PMCB — Pharmacyte Biotech Balance Sheet
0.000.00%
Annual balance sheet for Pharmacyte Biotech, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | 2026 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 85.4 | 68 | 50.2 | 18.5 | 37.1 |
| Net Total Receivables | — | — | — | 3.7 | 0.241 |
| Prepaid Expenses | |||||
| Total Current Assets | 85.5 | 68.1 | 50.4 | 22.4 | 37.4 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 90.6 | 73.3 | 59.9 | 55.2 | 46.8 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.704 | 0.587 | 7.42 | 2.91 | 0.826 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.704 | 0.587 | 20.4 | 3.28 | 11.8 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 89.9 | 72.7 | 39.5 | 51.9 | 35 |
| Total Liabilities & Shareholders' Equity | 90.6 | 73.3 | 59.9 | 55.2 | 46.8 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |